Robert W. Baird Initiates Coverage on Castle Biosciences (NASDAQ:CSTL)

Research analysts at Robert W. Baird assumed coverage on shares of Castle Biosciences (NASDAQ:CSTL) in a report released on Monday, MarketBeat reports. The brokerage set an “outperform” rating and a $27.00 price target on the stock. Robert W. Baird’s price objective points to a potential upside of 42.71% from the company’s previous close.

Separately, Canaccord Genuity assumed coverage on shares of Castle Biosciences in a research note on Monday. They issued a “buy” rating and a $26.00 target price on the stock. Five research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average target price of $26.80.

Shares of NASDAQ:CSTL opened at $18.92 on Monday. Castle Biosciences has a 52 week low of $17.11 and a 52 week high of $24.75.



In other news, major shareholder Mgc Venture Partners 2013 Gp, bought 312,500 shares of Castle Biosciences stock in a transaction dated Monday, July 29th. The shares were bought at an average price of $16.00 per share, for a total transaction of $5,000,000.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David S. Kabakoff bought 62,500 shares of Castle Biosciences stock in a transaction dated Monday, July 29th. The stock was purchased at an average price of $16.00 per share, for a total transaction of $1,000,000.00. The disclosure for this purchase can be found here.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue.

Featured Article: What are gap-down stocks?

Analyst Recommendations for Castle Biosciences (NASDAQ:CSTL)

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.